Islet transplantation offers a minimally invasive approach for b cell replacement in diabetic patients with hypoglycemic unawareness. Attempts at insulin independence may require multiple islet reinfusions from distinct donors, increasing the risk of allogeneic sensitization. Currently, solid organ pancreas transplant is the only remaining surgical option following failed islet transplantation in the United States; however, the immunologic impact of repeated exposure to donor antigens on subsequent pancreas transplantation is unclear. We describe a case series of seven patients undergoing solid organ pancreas transplant following islet graft failure with long-term follow-up of pancreatic graft survival and renal function. Despite highly variable panel reactive antibody levels prior to pancreas transplant (mean 27 AE 35%), all seven patients achieved stable and durable insulin independence with a mean follow-up of 6.7 years. Mean hemoglobin A1c values improved significantly from postislet, prepancreas levels (mean 8.1 AE 1.5%) to postpancreas levels (mean 5.3 AE 0.1%; p = 0.0022). Three patients experienced acute rejection episodes that were successfully managed with thymoglobulin and methylprednisolone, and none of these preuremic type 1 diabetic recipients developed stage 4 or 5 chronic kidney disease postoperatively. These results support pancreas-after-islet transplantation with aggressive immunosuppression and protocol biopsies as a viable strategy to restore insulin independence after islet graft failure.
Introduction
Current therapeutic options for b cell replacement to treat type 1 diabetes mellitus in nonuremic patients include solid organ pancreas transplantation and islet transplantation. Islet transplantation has shown great progress since its inception in the 1960s, with rates of insulin independence now >50% at 5 years in select patients. These advancements in islet transplantation provide an alternative route for b cell replacement, which avoids the morbidity of open abdominal surgery (1-7). However, when islet allografts fail after an extended period of insulin independence, repeat islet infusions can result in sensitization, exacerbated by multiple infusions from distinct deceased donors. Because the majority of current experimental protocols for islet transplantation exclude patients with failed alloislet transplants, solitary pancreas transplantation is the best remaining option to return to an insulin independent state. Although prior islet transplantation and sensitization increase risk for subsequent islet graft failure, their effects on subsequent pancreas transplant are unknown. In a prior study of sensitized pancreas transplant recipients, sensitization did not decrease graft survival following pancreas transplant (8) . A 9-year follow-up of 167 pancreas recipients showed that the presence of donorspecific antibodies (DSAs) increased the number of acute rejection episodes without a significant difference in graft or patient survival compared with patients without DSAs (8) . Nevertheless, pancreas transplants in the preuremic recipient are at higher risk of rejection with poorer overall long-term outcomes compared with simultaneous pancreas-kidney transplants (9) . Even with minimal sensitization, patients with failed islet allografts who desperately desire a return to insulin independence have been largely excluded from pancreas transplant due to their immunologic risk. The increasing frequency of pancreas-after-islet (PAI) transplantation was recently reported using registry data (10) and in a case report of two patients (11) . Given the limiting constraints of registry data, PAI has not been studied for the effect of prior sensitization on graft or patient outcomes. In this report, we identified a population of seven consecutive patients who received a solitary pancreas transplant after failed islet transplantation and followed long-term graft survival, insulin independence, and renal function.
Materials and Methods
Seven consecutive PAI patients receiving care at our institution from 2007 to 2016 were included in this study. For inclusion, patients were aged >18 years with a prior history of nonuremic type 1 diabetes and hypoglycemic unawareness and had previously received islet transplant with loss of C-peptide production prior to pancreas transplant. Six of the seven pancreas transplants were performed at our institution; one transplant was performed at another institution with subsequent follow-up care maintained at our institution. Records were retrospectively reviewed for data acquisition, and patient demographic data are included in Table 1 . Statistical analysis was performed using the paired Student t-test, with values expressed as median plus range or mean plus or minus standard deviation.
Islet transplantation
Human islets were isolated, cultured, and percutaneously infused into the portal system, as described previously (12) (13) (14) (15) . All patients had received one to three islet transplants (mean 1.7 AE 0.8; Table 1 ). Immunosuppressive protocols during islet transplantation varied, with patients either receiving glucocorticoid-free Edmonton protocol immunosuppression (16), belatacept-based immunosuppression (17) , or an efalizumab-based immunosuppression regimen (17, 18) . One patient (patient 5) underwent an infusion of fetal tissue as a commercial therapeutic for b cell replacement and did not receive immunosuppression following his infusion. To prevent sensitization, five of seven patients were maintained on low-dose immunosuppression following islet failure until time of PAI transplant ( Table 1) .
Pancreas transplantation
All donors and recipients were ABO compatible and were confirmed to have a negative virtual and/or physical crossmatch without DSAs prior to transplantation. Donor pancreata were prepared for transplant using a donor iliac artery Y-graft to the donor splenic and superior mesenteric arteries, as described previously (7, 19) . Heterotopic solid organ pancreas transplants were performed via midline laparotomy, with arterial anastomosis to the right iliac artery and systemic venous drainage by anastomosis to the recipient iliac vein. Enteric drainage of pancreatic exocrine secretions was established by side-to-side anastomosis of the graft duodenum to the recipient ileum. All patients received 4-5 days of prophylactic anticoagulation postoperatively.
Immunosuppressive therapy
For PAI transplant immunosuppression, induction therapy consisted of anti-thymocyte globulin (thymoglobulin, 6 mg/kg) and methylprednisolone. Standard four-drug maintenance therapy included low-dose tacrolimus (TAC; trough 5-7 ng/mL), mycophenolic acid (MPA; 360-720 mg twice daily), and prednisone 5 mg daily. Low-dose mammalian target of rapamycin (mTOR) inhibition with sirolimus or everolimus (trough 5-7 ng/mL) was added 1 mo following transplant, with subsequent reduction of MPA dosage to 360 mg orally twice daily. The strategy for long-term maintenance was quadruple therapy, with low levels of TAC, MPA, and mTOR inhibitors to avoid the toxicities of these agents. If patients developed oral ulcers, significant proteinuria (urine protein: creatinine ratio >1 g/g) or other toxicities associated with mTOR inhibitors, this drug was discontinued and MPA was increased to full dose. TAC was targeted to lower trough levels in all recipients to minimize nephrotoxicity in this preuremic population. Maintenance of immunosuppression at 1 year following transplantation is listed in Table 2 .
Graft surveillance and management of rejection
Protocol pancreas biopsies were performed on all patients undergoing PAI transplantation at our institution, targeted between 2 and 6 mo postoperatively. One patient (patient 4) had a delayed protocol biopsy due to recovery from an unrelated extremity operation, whereas a second patient (patient 5) had an inaccessible graft by percutaneous access on first attempt; a repeated attempt 6 mo later was successful. For-cause pancreas biopsies were performed for clinical and/or laboratory findings Edmonton protocol consists of sirolimus, everolimus, and daclizumab (16) . PRA, panel reactive antibody; T1DM, type 1 diabetes mellitus; Tx, transplantation.
concerning for rejection, including elevation of serum amylase or lipase, graft pain, fever of unclear etiology, and/or elevated serum glucose.
Patients who experienced acute rejection were managed with thymoglobulin (3 mg/kg for grade 1 rejection, 6 mg/kg for grade 2 or 3 rejection) and methylprednisolone (125 mg 9 2 days, with rapid taper to baseline prednisone dose). If trough levels of TAC or sirolimus were below targeted levels, doses were adjusted accordingly.
Posttransplant prophylaxis and follow-up
All PAI transplant recipients received a standardized prophylactic antimicrobial regimen early after transplant. All recipients were treated with piperacillin/tazobactam for 5 days postoperatively until donor duodenal cultures were finalized. If donor cultures returned positive, antibiotics were focused according to sensitivities and continued to complete a 10-day course. Fluconazole was administered for fungal prophylaxis, with 400 mg administered intravenously at time of transplant, followed by 200 mg intravenously for 5 days postoperatively. If donor cultures returned positive for yeast, fluconazole was continued for a 30-day course. Patients continued fungal prophylaxis orally for 2 mo following transplant. Sulfamethoxazole/trimethoprim was administered daily for 1 mo and then three times weekly for Pneumocystis pneumonia prophylaxis. Patients were followed regularly in clinic for the first 6 mo (post-operative weeks 1, 2, 3, 4, 6, 8, 12, 24) with routine laboratory monitoring; subsequently patients underwent laboratory studies on a monthly basis and returned to clinic for routine follow-up every 6 mo.
Results

Patient characteristics
Seven patients met inclusion criteria for PAI transplantation; five were female and two male, ranging in age from 27 to 51 years at the time of PAI transplant. 
Posttransplant graft and renal function
Patients underwent pancreas transplant following failed islet transplantation between October 2006 and May 2014, with follow-up ranging from 26 to 118 mo. No patients were lost to follow-up. All patients were monitored regularly for self-identified episodes of symptomatic hypoglycemia and HbA1c levels. Figure 1 shows postoperative pancreatic and renal outcomes. At the most recent follow-up, HbA1c values ranged from 5.1% to 5.4% (mean 5.3 AE 0.1%). From time of transplant, the mean improvement in HbA1c was 2.8 AE 1.5% (p = 0.0022), with all patients remaining insulin independent with normal HbA1c (Figure 1A-B) . With the exception of the immediate posttransplant period, all patients remained entirely insulin independent for the duration of follow-up. Three of seven patients were found to have proteinuria by urine protein:creatinine ratio; one patient had one isolated episode of proteinuria (patient 6, 348 mg/g), whereas two patients had sustained proteinuria (patients 1 and 3; peak 950 and 246 mg/g, respectively). Despite a mean decrease in GFR of 20.0 AE 16 mL/min per 1.73 m 2 (p = 0.017; Figure 1B ) and an overall increase in serum creatinine of 0.3 AE 0.2 mg/dL (p = 0.015; Figure 1C ), no patients progressed to stage 4 or 5 chronic kidney disease, and all patients maintained serum creatinine <1.5 mg/dL.
Graft survival and rejection episodes
All patients underwent protocol pancreas biopsies within the first year of transplant. Three of seven patients were diagnosed with one episode of rejection, whereas four patients had no rejection on protocol biopsy or clinical follow-up (Table 3) . Of the three patients who experienced rejection episodes, two were diagnosed by protocol biopsy in the absence of clinical signs or symptoms. One patient (patient 4) showed grade 1 acute cellular rejection (ACR) on histology, and one patient (patient 2) revealed grade 3 ACR on histology. Rejection episodes were treated with thymoglobulin (3 mg/kg for grade 1 and 6 mg/kg for grade 3 ACR) and methylprednisolone. No additional biopsies were performed, and these patients remained free of clinical rejection for the remainder of the study period. One patient (patient 5) experienced clinical rejection, as identified by fever, graft pain, and elevated serum amylase to 666 U/L. This single episode of early rejection occurred 2 weeks after transplant, and the rejection episode was successfully managed with methylprednisolone. Based on the patient's clinical syndrome and exclusion of other causes on workup, no biopsy was performed at that time. A delayed protocol biopsy performed at 6 mo after transplant showed no signs of histologic rejection, and the patient had no further episodes of clinical rejection. One patient (patient 1) underwent two for-cause biopsies at an outside institution based on suspicion of rejection; both biopsies confirmed normal pancreas histology without evidence of rejection.
Posttransplant complications
Nonimmunologic complications following pancreas transplant are listed in Table 3 . Nine total complications in six patients occurred during the postoperative period. These included anemia and oral ulcers (patient 2), recurrent urinary tract infections requiring antibiotic therapy (patient 3), a peripancreatic abscess successfully managed with percutaneous drainage and antibiotic therapy (patient 4), a facial squamous cell cancer requiring surgical resection (patient 6), and an episode of bronchitis requiring antibiotic therapy (patient 7). In addition, two patients experienced three small bowel obstructions (patients 1 and 3) requiring lysis of adhesions; patient 1 had recurrent intra-abdominal adhesive disease requiring lysis of adhesions twice, and patient 3 experienced a small bowel obstruction secondary to adhesive disease and an internal hernia at the anastomosis. Three patients required discontinuation of mTOR inhibitor based on side effects, including anemia and oral ulcers (patient 2), recurrent infections (patient 3), and insomnia and gastrointestinal distress (patient 4). All complications resolved, and all patients remain in routine follow-up.
Discussion
This is the largest case series describing patients who have undergone solid organ pancreas transplant following failed islet transplants. Islet transplantation has been associated with allogeneic sensitization following islet failure in some recipients, although repeated islet infusion from additional donors has not necessarily led to further sensitization risks (20) . The results of this case series suggest that PAI transplantation is a viable strategy to achieve long-term insulin independence in patients with nonuremic type 1 diabetes. Our rates of graft rejection episodes are comparable to other published reports of solitary pancreas transplants and simultaneous kidney-pancreas transplants (21, 22) . Importantly, all seven patients demonstrated preservation of insulin independence, with no deterioration of graft function as a result of early subclinical or clinical rejection episodes. These results are especially promising because these patients have maintained long-term insulin independence regardless of their pretransplant PRA positivity. Although elevated PRA remains a marker of sensitization, elevated PRA resulting from islet transplantation should not be a contraindication to subsequent pancreas transplant. These findings require further validation in larger follow-up studies, but our results suggest that PAI is an excellent modality for achieving insulin independence in the management of type 1 diabetes following a failed islet transplant. Moreover, repeated islet infusions are not supported by most third-party payers in the United States, making solitary pancreas transplants the only option to return to a state of insulin independence following a failed islet transplant.
Of the three rejection episodes in our cohort, two were subclinical and identified on routine protocol biopsy alone; only one patient experienced a single episode of clinical rejection. We believe that early protocol biopsy is an essential tool for rapid detection and treatment of subclinical rejection in sensitized patients undergoing PAI transplant. Increased surveillance by protocol biopsy limits damage to the allograft when subclinical rejection does occur, helping to promote favorable long-term graft outcomes through early intervention. In cases where histologic rejection is identified, our protocol is to treat for rejection without repeated biopsy to confirm resolution of rejection because the benefits of further monitoring must be balanced against the risk of traumatic allograft injury (23) . Although not performed on the seven patients included in this study, we now routinely evaluate pancreas recipients for the presence of autoantibodies on a prospective basis to further monitor for risk of immune-mediated graft injury.
Preservation of renal function is another priority in the preuremic diabetic population. To minimize nephrotoxicity, we use a four-drug immunosuppression strategy to minimize calcineurin inhibitor (CNI) exposure with a goal TAC trough level of 5-7 ng/mL. Prior to transplant, five of seven patients had preexisting stage 2 chronic kidney disease, stressing the importance of renal preservation. Overall, we observed a mild but statistically significant change in renal function over the course of the study, with a mean increase in serum creatinine of 0.3 AE 0.2 mg/dL (p = 0.015) and a mean decrease in GFR of 20.0 AE 16 mL/ min per 1.73 m 2 (p = 0.017). Three patients progressed to stage 3 chronic kidney disease, and four patients maintained their pretransplant renal function, whereas all patients maintained serum creatinine levels <1.5 mg/dL. Although normoglycemia following successful PAI transplant prevents the progression of diabetic glomerulopathy (24) , the slight deterioration of renal function seen in this cohort emphasizes that CNI minimization remains the greatest modifiable risk factor to protect renal function following PAI transplant. We feel that maintaining consistently low CNI levels without compromising low rejection rates is critical to successful PAI transplantation. Along these lines, we have an ongoing study protocol to determine the efficacy of costimulation blockade as a nonnephrotoxic immunosuppressive agent to permit lower doses of CNIs. When episodes of acute kidney injury did occur postoperatively, the majority were associated with supratherapeutic TAC trough levels, stressing the importance of CNI minimization to preserve long-term renal function in this preuremic transplant population. This study is limited by its small sample size and the inherently observational nature of a case series. In this observational study, DSAs were not routinely monitored postoperatively but would further characterize the immunologic response to PAI transplant. Gruessner et al first reported the prevalence of this new pathway to insulin independence based on a review of International Pancreas Transplant Registry and United Network for Organ Sharing data (10) . Although the results of their review further support the efficacy of PAI transplantation, wider applicability of that data set is limited by the heterogeneity of maintenance immunosuppression and rejection treatment protocols for pancreas transplant. The aggressive immunosuppressive strategy and monitoring protocol used in this single-center series resulted in long-term (6.7-year) insulin independence in this immunologically challenging group of sensitized preuremic pancreas transplant recipients. The high frequency of postoperative complications associated with pancreas transplantation reflect the technical challenges of this procedure. Nonetheless, this is the best strategy to return to the state of insulin independence enjoyed by these islet recipients prior to loss of islet function.
In conclusion, this study highlights PAI transplantation as a successful strategy to achieve long-term insulin independence in nonuremic type 1 diabetic patients despite the presence of sensitization from prior failed islet allografts. The use of a multidrug immunosuppression regimen that minimizes CNI dosage remains essential to preservation of renal function in this nonuremic population. Protocol biopsy should be performed in all patients to ensure longterm graft survival, although sensitization from failed islet transplantation should not be considered a contraindication to subsequent pancreas transplantation.
